Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Issue 1 (February 2014)

• Record Type: Journal Article
• Authors: Duployez, Nicolas; Willekens, Christophe; Marceau-Renaut, Alice; Boudry-Labis, Elise; Preudhomme, Claude
• Is Part Of: Expert review of hematology. Volume 8:Issue 1(2015)
• Page Start: 43
• Page End: 56
• Publication Date: 2014-02
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1586/17474086.2014.976551
• Languages: English
• ISSNs: 1747-4086

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Core-binding factor acute myeloid leukemia (CBF-AML) – including AML with t(8;21) and AML with inv(16) – accounts for about 15% of adult AML and is associated with a relatively favorable prognosis. Nonetheless, relapse incidence may reach 40% in these patients. In this context, identification of prognostic markers is considered of great interest. Due to similarities between their molecular and prognostic features, t(8;21) and inv(16)-AML are usually grouped and reported together in clinical studies. However, considerable experimental evidences have highlighted that they represent two distinct entities and should be considered separately for further studies. This review summarizes recent laboratory and clinical findings in this particular subset of AML and how they could be used to improve management of patients in routine practice.</p> </abstract>